Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22032261 | 0.83 | TSHR (0.38) | CHRM2CHRM1CHRM3 | |
| SCHEMBL17317783 | 0.83 | POLB (0.37) | CHRM1 | |
| SCHEMBL3817178 | 0.82 | BRD4 (0.47) | NR1H2BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL3817176 | 0.82 | BRD4 (0.47) | NR1H2BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL30777203 | 0.80 | CHRM2 (0.60) | NR1H2BRD4CACNA1HCHRM2CHRM1 | |
| SCHEMBL17317727 | 0.74 | BRD4 (0.42) | NR1H2BRD4LTA4H | |
| SCHEMBL10248813 | 0.74 | BRD4 (0.44) | NR1H2BRD4 | |
| SCHEMBL14599397 | 0.74 | BRD4 (0.44) | NR1H2BRD4LTA4H | |
| SCHEMBL6838735 | 0.74 | ESR1 (0.45) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL3951957 | 0.74 | ESR1 (0.45) | NR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891143-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115506-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |